EU reg­u­la­to­ry com­mit­tee rec­om­mends 8 new drugs for ap­proval, in­clud­ing Bris­tol My­er­s' BC­MA CAR-T

At its June meet­ing, the Eu­ro­pean Med­i­cine Agency’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use rec­om­mend­ed eight new drugs for ap­proval, bring­ing this year’s count to 50 pos­i­tive opin­ions.

While the Eu­ro­pean Com­mis­sion doesn’t need to fol­low the CHMP’s rec­om­men­da­tions, it typ­i­cal­ly does. Here are the drugs that got the com­mit­tee’s green light this month:


A few months af­ter be­com­ing the first mar­ket­ed BC­MA CAR-T ther­a­py, blue­bird and Bris­tol My­ers Squibb’s Abec­ma (al­so known as ide-cel) has snagged a CHMP rec­om­men­da­tion for con­di­tion­al mar­ket­ing ap­proval in re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma. The com­mit­tee rec­om­mends the drug as a fourth-line ther­a­py, af­ter pa­tients have tried an im­munomod­u­la­to­ry agent, a pro­tea­some in­hibitor and an an­ti-CD38 an­ti­body.

Abec­ma’s US ap­proval came about a year af­ter BMS and blue­bird got slammed with a sur­prise refuse-to-file let­ter. Reg­u­la­tors based their de­ci­sion on da­ta from the piv­otal Phase II Kar­M­Ma tri­al, which showed that among 100 pa­tients tak­ing ide-cel, 72% saw their tu­mors shrink and 28% achieved a strin­gent com­plete re­sponse. An es­ti­mat­ed 65% of those had re­mis­sion last­ing at least 12 months, the com­pa­nies said.

“As the first CAR T cell ther­a­py for re­lapsed and re­frac­to­ry mul­ti­ple myelo­ma to re­ceive a pos­i­tive CHMP opin­ion, Abec­ma rep­re­sents a po­ten­tial new treat­ment ap­proach for pa­tients in Eu­rope bat­tling this in­cur­able blood can­cer,” said Noah Berkowitz, BMS’ se­nior VP of cell ther­a­py de­vel­op­ment, in a state­ment.

The part­ners said back in March that the drug would have a US list price of $419,500.

How­ev­er, ri­vals like J&J and Leg­end are catch­ing up. Cil­ta-cel was grant­ed pri­or­i­ty re­view in May, the same month the part­ners re­leased Phase II da­ta show­ing a 95% over­all re­sponse rate, with a 75% strin­gent com­plete re­sponse rate. Those da­ta are part of the pack­age J&J is sub­mit­ting in rolling ap­pli­ca­tions for ap­provals in Eu­rope and the US.

BMS al­so came away with an­oth­er CHMP win, as the com­mit­tee rec­om­mend­ed ex­pand­ing Op­di­vo’s la­bel to in­clude the ad­ju­vant treat­ment of adults with esophageal or gas­troe­sophageal junc­tion can­cer fol­low­ing pri­or ther­a­py.


Bio­Marin’s vosori­tide is still await­ing a de­ci­sion from the FDA, but the CHMP has rec­om­mend­ed an OK for the treat­ment of achon­dropla­sia, a con­di­tion that caus­es dwarfism.

The CHMP’s rec­om­men­da­tion cov­ers pa­tients two years and old­er un­til their growth plates are closed, which oc­curs af­ter pu­ber­ty when chil­dren reach their fi­nal adult height.

Up­on get­ting vosori­tide across the FDA’s doorstep back in No­vem­ber, Bio­Marin said the drug spurred an­nu­al growth of 1.57 cm over place­bo and pa­tients, on av­er­age, gained 2.2 cm in height com­pared to what nat­ur­al his­to­ry sug­gest­ed they would in a Phase III study. Phase II da­ta sug­gest that the drug helped add up to 9.0 cm in cu­mu­la­tive ad­di­tion­al height over 4 and a half years. That was in pa­tients 5 to 18 years old. How­ev­er, the FDA made it clear that a pan­el of out­side ex­perts had rec­om­mend­ed two-year con­trolled tri­als across dif­fer­ent age groups.

Reg­u­la­tors had ini­tial­ly set an Au­gust 2021 PDU­FA date, then ex­tend­ed the de­ci­sion un­til No­vem­ber af­ter Bio­Marin sub­mit­ted two-year re­sults from a Phase III ex­ten­sion study.


Al­most a year af­ter the FDA grant­ed Mor­phoSys and In­cyte a quick okay on Mon­ju­vi, the CHMP has giv­en the CD19-tar­get­ing mon­o­clon­al an­ti­body a rec­om­men­da­tion in re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL).

The con­di­tion­al mar­ket­ing au­tho­riza­tion would like­ly come for taf­a­sita­m­ab in com­bo with lenalido­mide, fol­lowed by taf­a­sita­m­ab monother­a­py in pa­tients who aren’t el­i­gi­ble for au­tol­o­gous stem cell trans­plant, ac­cord­ing to the CHMP’s opin­ion.

The drug, which would be mar­ket­ed as Min­ju­vi in Eu­rope, raked in $22 mil­lion from its launch last Au­gust to the end of De­cem­ber. Re­sults re­leased last May showed a 59% re­sponse rate, a 39% com­plete re­sponse rate, and a me­di­an du­ra­tion of re­sponse of  34.6 months — near­ly 3 years.

“Pa­tients with re­lapsed or re­frac­to­ry DL­B­CL have lim­it­ed treat­ment op­tions and of­ten face a poor prog­no­sis. There is an ur­gent need for ef­fec­tive ther­a­pies and if ap­proved, this com­bi­na­tion could pro­vide pa­tients in Eu­rope with an im­por­tant new ther­a­peu­tic op­tion,” said Malte Pe­ters, Mor­phoSys’ chief R&D of­fi­cer.

In­cyte and Mor­phoSys share glob­al de­vel­op­ment rights to taf­a­sita­m­ab, and In­cyte has ex­clu­sive com­mer­cial­iza­tion rights to taf­a­sita­m­ab out­side the Unit­ed States.


Bel­gium’s UCB isn’t ex­pect­ing an an­swer from the FDA on its bimek­izum­ab un­til Oc­to­ber. But the CHMP has giv­en it the thumbs-up for the treat­ment of mod­er­ate to se­vere plaque pso­ri­a­sis.

Over the last cou­ple of years, UCB has claimed Phase III wins against J&J’s block­buster Ste­lara, Ab­b­Vie’s Hu­mi­ra, and No­var­tis’ Cosen­tyx.

Cosen­tyx blocks in­ter­leukin-17F, one of the IL-17 cy­tokines in­volved in pso­ri­a­sis. The idea be­hind bimek­izum­ab was that by block­ing both in­ter­leukin 17s in­volved in pso­ri­a­sis — IL-17F and IL-17A — you could have a stronger ef­fect.

UCB says 58.6% of pa­tients who took bimek­izum­ab were com­plete­ly cleared of skin le­sions af­ter 16 weeks, com­pared to 20.9% of pa­tients on Ste­lara. It al­so out­per­formed Ste­lara at how many pa­tients were clear af­ter one year and at less­er bench­marks for plaque clear­ance, with more than 8 out of 10 pa­tients show­ing 90% im­prove­ment, com­pared to rough­ly half on Ste­lara, the com­pa­ny said.

When pit­ted against a place­bo, bimek­izum­ab helped 68% of pa­tients achieve com­plete­ly clear skin, and more than 90% see a 90% im­prove­ment, ac­cord­ing to Phase III da­ta re­leased in 2019. For place­bo that num­ber was 1.2%.

Back in April, the FDA set a PDU­FA date for Oct. 15.


Just as Genen­tech’s long-run­ning block­buster Lu­cen­tis is set to lose patent pro­tec­tion in Eu­rope, the CHMP has rec­om­mend­ed an OK for Sam­sung Bioepis and Bio­gen’s biosim­i­lar, dubbed By­ooviz.

The com­mit­tee is rec­om­mend­ing the drug for use in a slate of vi­su­al im­pair­ments in­clud­ing: wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, vi­su­al im­pair­ment due to di­a­bet­ic mac­u­lar ede­ma, pro­lif­er­a­tive di­a­bet­ic retinopa­thy, vi­su­al im­pair­ment due to mac­u­lar ede­ma sec­ondary to reti­nal vein oc­clu­sion (branch RVO or cen­tral RVO), and vi­su­al im­pair­ment due to choroidal neo­vas­cu­lar­i­sa­tion.

Lu­cen­tis was first ap­proved for wet AMD in the US back in 2006. In 2017, it be­came the first FDA-ap­proved treat­ment for all forms of di­a­bet­ic retinopa­thy, the lead­ing cause of blind­ness in work­ing-age adults, back in 2017. How­ev­er, the mar­ket’s now crowd­ed with long-act­ing AMD drugs, in­clud­ing Re­gen­eron’s Eylea and No­var­tis’s Beovu.

“Biosim­i­lars could help broad­en ac­cess and of­fer sig­nif­i­cant health­care sav­ings through the treat­ment of these com­plex and of­ten de­bil­i­tat­ing oph­thalmic dis­eases,” said Ian Hen­shaw, Glob­al Head of Biosim­i­lars at Bio­gen.


Eu­rope could soon have its first oral in­hibitor of hy­pox­ia-in­ducible fac­tor (HIF) pro­lyl hy­drox­y­lase (PH), ac­cord­ing to Astel­las and Fi­bro­Gen.

The CHMP gave rox­adu­s­tat — which would be mar­ket­ed as Evren­zo — a pos­i­tive opin­ion for the treat­ment of ane­mia in pa­tients with chron­ic kid­ney dis­ease. The drug is al­ready ap­proved in this in­di­ca­tion in Japan, Chi­na and Chile, and is un­der re­view in the US.

The drug ran in­to trou­ble back in April, when Fi­bro­Gen back­tracked on some of its key safe­ty da­ta. Ac­cord­ing to CEO En­rique Con­ter­no, Fi­bro­Gen ex­ecs be­came “aware” that their analy­sis in­clud­ed post hoc changes to strat­i­fi­ca­tion fac­tors used to as­sess the haz­ard ra­tio of their drug — es­sen­tial­ly ma­nip­u­lat­ing the da­ta to en­hance how much the ther­a­py re­duced key risks for pa­tients and shar­ing that false pro­file with in­vestors and reg­u­la­tors. Us­ing pre-spec­i­fied strat­i­fi­ca­tion fac­tors raised the risk on key safe­ty end­points, which re­volved pri­mar­i­ly around MACE, a com­pos­ite end­point of all-cause mor­tal­i­ty, stroke, and my­ocar­dial in­farc­tion.

Shares plunged on the news, evis­cer­at­ing about a bil­lion dol­lars of Fi­bro­Gen’s mar­ket cap.

Two more gener­ics

The CHMP has al­so rec­om­mend­ed mar­ket­ing au­tho­riza­tion for two gener­ics: Abi­raterone My­lan (al­so known as abi­raterone ac­etate, a gener­ic to Janssen’s Zyti­ga) for metasta­t­ic prostate can­cer and Fin­golimod My­lan (fin­golimod, a gener­ic to No­var­tis’ Gilenya) for re­laps­ing-re­mit­ting mul­ti­ple scle­ro­sis with high dis­ease ac­tiv­i­ty.

Australia’s Avance Clinical: no IND required and a 43.5% rebate on clinical spend for CGT biotechs

No IND Re­quired for Cell and Gene Ther­a­py Stud­ies with Aus­tralia’s Ac­cred­it­ed CRO Avance Clin­i­cal

Avance Clinical is the specialist Australian CRO, with CGT accreditation, for international biotechs that leverages Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend.

Learn more about Avance ClinicReady here.
Contact us about your next study.
Download our Frost & Sullivan APAC CRO Report here. 

The cell and gene therapies (CGT) sector offers unprecedented opportunities for patient disease management across virtually all therapeutic areas. However, finding the right accredited clinical teams to take a therapy through to the clinic and manage the regulatory process can be a major challenge for biotechs with a CGT product.

Ursula von der Leyen, President of the European Commission

Omi­cron: Re­searchers scram­ble as new coro­n­avirus mu­ta­tion takes flight around the globe — Pfiz­er/BioN­Tech, Mod­er­na vow swift re­sponse

As Americans were waking up for their Black Friday rituals, they were greeted with the news that a new mutation of the Covid-19 virus has appeared and been sequenced — after it caught an international flight to Hong Kong. And two of the leading Covid-19 vaccine developers promised delivery of a new vaccine “within 100 days” if necessary while a third spelled out its 3-prong strategy hours later.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Thanks­giv­ing edi­tion: Top 15 End­points sto­ries of 2021; Can you name that vac­cine?; Mer­ck­'s Covid an­tivi­ral dis­ap­points; FDA nom­i­nee's in­dus­try ties; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Happy Thanksgiving to all those who are celebrating it — although, if we are being honest, this week’s abbreviated edition is really for those who are not. Wherever you’re tuning in from, we appreciate your support, hope you find this recap helpful and we wish you a wonderful weekend.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Troy Wilson, Kura CEO

UP­DAT­ED: FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

The FDA has slapped a clinical hold on the early-stage program for one of Kura Oncology’s cancer drugs following a patient’s death in a clinical trial.

The biotech $KURA reported early Wednesday that the Phase Ib study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probed the death. Patients already on the drug can continue taking it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

What were End­points read­ers tun­ing in­to this year? Here’s a look at our 15 most pop­u­lar re­ports of the year (so far)

At the beginning of this year, I laid out a basic objective for Endpoints News as we headed to our 5th anniversary. We’ve long been doing a fine job covering the breaking news in R&D — if I do say so myself — but we needed to expand our horizons on industry coverage, increase the staff and go much, much deeper when the stories demanded it.

In a phrase: broader and deeper.

It’s safe to say, based on our daily web traffic, that you all seemed to like this idea. We’ve doubled the staff — thanks to a growing group of paid subscribers — ramped up the daily report and now publish a regular slate of in-depth articles. And traffic — those clicks you always read about — have gone up in volume too. Monthly sessions are up 43%, to close to 1.5 million. Unique readers are up 63%, to 874,480 in October, after setting a record of close to a million the month before. Page views are running at 3 million-plus a month. And the overall number of subscribers has surged to 124,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: Am­gen, Lil­ly, Bio­haven mi­graine brand re­call low, study says; No­var­tis looks to re­make drug launch mod­el

Forget the migraine marketing brand wars. When it comes to patients, many can’t even name one despite substantial advertising efforts, according to a new study from Phreesia that concludes CGRP migraine drugmakers still need to work on brand recognition.

Almost half (47%) of the patients Phreesia surveyed couldn’t name one preventative migraine brand. The best performer was Topamax, a small molecule anticonvulsant that’s been around since 2004, which 26% of migraine patients could recall. Among the new CGRP brand names recognized, Amgen’s Aimovig ranked highest with 8% recall, while Eli Lilly’s Emgality and Biohaven’s Nurtec tied at 7% and Teva’s Ajovy was remembered by 3% of patients.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Robert Davis, Merck CEO

Mer­ck shares slide as re­sponse to its oral Covid an­tivi­ral plunges on lat­est up­date

After a second look, Merck says that its big breakthrough on the Covid front doesn’t look so good.

The pharma giant updated its data on its oral antiviral molnupiravir on Friday, and said that its drug reduced the rate of hospitalization and death by 30% — a sharp plunge from the 50% rate reported at the beginning of October during their interim readout.

And the news sparked a sharp retreat on Merck’s shares, which fell 4% ahead of the bell on Friday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)

Glax­o­SmithK­line places a risky bet on Ar­row­head­'s RNA drug in the fail­ure-strewn NASH field

As activist investors champ at the bit for change at drug giant GlaxoSmithKline, the pharma giant has turned over many rocks to find an R&D success to present to its detractors. In NASH, a field strewn with failures, GSK hopes a new license deal can churn out a much-needed winner.

GSK will pay $120 million in upfront cash and $910 million in downstream milestones to develop and sell ARO-HSD, Arrowhead Pharmaceuticals’ RNA interference drug targeting fatty liver disease nonalcoholic steatohepatitis (NASH), the companies said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Name that vac­cine: From Comir­naty to Spike­vax to Nu­vax­ovid, Covid-19 shot­s' brand names re­main lit­tle-known

Most people know if they’re “Team Pfizer” or “Team Moderna,” but few know if they got the Comirnaty or Spikevax Covid-19 vaccine. Those are the brand names of Pfizer and Moderna vaccines, respectively, however they have yet to take hold with consumers, media or even medical professionals.

And there are others. Covid vaccine brand names also include AstraZeneca’s Vaxzevria, Novavax’s Nuvaxovid, and Sanofi and GlaxoSmithKline’s Vidprevtyn. J&J’s Janssen-developed Covid vaccine is the lone major holdout and is still yet to be named, if ever. In EMA filings approving its conditional use, the brand name is listed simply as “Covid-19 Vaccine Janssen.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.